Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: A parenteral nutrition including at least one of an amino acid, a dextrose, a lipid, an electrolyte or a mixture thereof and a trace element including at least one of zinc, copper, selenium, or manganese is provided. The parenteral nutrition including the trace element is stable for about at least 3 days to about 14 days. Methods of preparing and using the stable injectable parenteral nutrition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 µg to about 4,000 µg of zinc, about 40 µg to about 400 µg of copper, from about 4 µg to about 90 µg of selenium, or from about 1 µg to about 80 µg of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: A parenteral nutrition including at least one of an amino acid, a dextrose, a lipid, an electrolyte or a mixture thereof and a trace element including at least one of zinc, copper, selenium, or manganese is provided. The parenteral nutrition including the trace element is stable for about at least 3 days to about 14 days. Methods of preparing and using the stable injectable parenteral nutrition are also provided.

Abstract: Pharmaceutical formulations of bendamustine for pharmaceutical use and methods related thereto. The formulations and methods described herein utilize a polar aprotic solvent, or mixture thereof, that can be used to produce lyophilized bendamustine.

Abstract: The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature.

Abstract: The present invention provides a manufacturing process for liposomal preparations comprising water-insoluble or hydrophobic active principals. In accordance with one aspect of the inventive method, at least one active principal and lipid fraction are dissolved in an organic solvent. This solution is then subjected to reduced pressure (vacuum) in a container with or with out inert packing to remove the organic solvent, thereby forming a puffy cake comprising the active principal or principals and lipid fraction. This puffy cake is then mixed with an aqueous solution, under controlled conditions suitable to form a bulk liposomal preparation. Because the active principal is imbedded in the lipid bilayer, removal of the aqueous solution is optional.

Abstract: The present invention provides a composition comprising a physiologically acceptable carrier and two or more agents encapsulated in a liposome, wherein the combination of the two or more agents possess the following properties: (1) cytotoxicity to tumor cells, (2) nutritional properties, (3) use in application to nails, hair, skin or lips or (4) activity against parasites and insects. The invention also provides a method of making such a composition. The invention further provides a method of treating cancer when the combination of the two or more agents is cytotoxic to tumor cells.

Abstract: The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature.